Kessler Topaz Meltzer & Check, LLP filed a securities fraud class action against GeneDx Holdings Corp. in the U.S. District Court for the District of Connecticut on June 28, 2026, alleging that investors who purchased shares of the company's NASDAQ-listed stock, ticker WGS, suffered losses during a defined class period [1]. The case is captioned Taher Basma v. GeneDx Holdings Corp., No. 26-cv-00880 [1].
The complaint covers investors who purchased WGS shares between April 16, 2025, and May 4, 2026, a period during which the stock experienced material losses [1]. Securities fraud class actions of this type arise under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, which prohibit materially false or misleading statements made in connection with the purchase or sale of securities. GeneDx is a genomics company that offers whole-genome sequencing services and has been publicly traded on the NASDAQ exchange [1].
The filing follows the standard procedural architecture of the Private Securities Litigation Reform Act of 1995. Under the PSLRA, the court will appoint a lead plaintiff, typically the movant with the largest financial interest in the litigation, after a statutory notice period. The lead plaintiff deadline in this case is August 3, 2026 [1]. Kessler Topaz, a firm with an established practice in institutional investor securities litigation, filed the initial complaint and will seek appointment as lead counsel pending that process.
The case joins a pattern of shareholder suits targeting healthcare technology companies whose stock prices declined sharply following the class period's close. The outcome will turn, in substantial part, on whether plaintiffs can establish that GeneDx made actionable misstatements or omissions during the class period and that those statements caused the identified losses. GeneDx has not yet filed a responsive pleading, and no court rulings on the merits have issued. The next procedural milestone is the August 3 lead plaintiff deadline, after which the court will consolidate any competing motions and enter a scheduling order.